Case report: use of lenzilumab and tocilizumab for the treatment of coronavirus disease 2019.
Immunotherapy
; 12(15): 1121-1126, 2020 10.
Article
in English
| MEDLINE | ID: covidwho-602002
ABSTRACT
Background:
Coronavirus disease 2019 (COVID-19) is a novel disease associated with a cytokine-mediated, severe, acute respiratory syndrome. Tocilizumab and lenzilumab are recombinant monoclonal antibodies against IL-6 and granulocyte macrophage colony-stimulating factor, respectively, and have been proposed as a potential treatment for acute, hypoxic respiratory failure associated with COVID-19. Results &methodology:
We present the case of a 68-year-old man with COVID-19 who was initially treated with hydroxychloroquine and lenzilumab, but continued to develop hypoxemia, requiring an increase in respiratory support with an associated rise in serum inflammatory markers. He was subsequently treated with tocilizumab with marked clinical improvement and a decrease in acute phase reactants within 48 h. Discussion &conclusion:
This case demonstrates the effective use of tocilizumab in the treatment of COVID-19 and suggests the superiority of tocilizumab over lenzilumab in the management of this cytokine-mediated syndrome.Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Pneumonia, Viral
/
Coronavirus Infections
/
Antibodies, Monoclonal, Humanized
Type of study:
Case report
/
Prognostic study
Limits:
Aged
/
Humans
/
Male
Language:
English
Journal:
Immunotherapy
Journal subject:
Allergy and Immunology
/
Therapeutics
Year:
2020
Document Type:
Article
Affiliation country:
Imt-2020-0136
Similar
MEDLINE
...
LILACS
LIS